Intuitive Surgical (NASDAQ:ISRG) PT Raised to $435.00 at Piper Sandler

Intuitive Surgical (NASDAQ:ISRG) had its price target hoisted by Piper Sandler from $425.00 to $435.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s price target would indicate a potential upside of 18.54% from the company’s previous close.

A number of other equities analysts have also recently issued reports on ISRG. Jefferies Financial Group upped their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday. Robert W. Baird decreased their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday. Mizuho upped their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Raymond James upped their price target on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Finally, Royal Bank of Canada upped their price target on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research report on Wednesday, January 24th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $381.24.

Intuitive Surgical Stock Down 1.5 %

Shares of ISRG stock traded down $5.65 during mid-day trading on Friday, reaching $366.98. 2,439,928 shares of the company’s stock traded hands, compared to its average volume of 1,654,617. Intuitive Surgical has a 12 month low of $254.85 and a 12 month high of $403.76. The company has a market cap of $130.08 billion, a P/E ratio of 73.65, a P/E/G ratio of 5.81 and a beta of 1.36. The company’s 50-day moving average price is $387.27 and its 200-day moving average price is $342.60.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The company’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.00 EPS. Equities analysts predict that Intuitive Surgical will post 4.93 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the sale, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Fredrik Widman sold 5,041 shares of Intuitive Surgical stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $397.07, for a total transaction of $2,001,629.87. Following the completion of the sale, the vice president now owns 110 shares of the company’s stock, valued at $43,677.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 329 shares of Intuitive Surgical stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $390.16, for a total value of $128,362.64. Following the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,148,611.12. The disclosure for this sale can be found here. Insiders sold 248,418 shares of company stock valued at $95,927,097 over the last quarter. 0.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its position in Intuitive Surgical by 0.3% during the fourth quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock valued at $3,002,000 after acquiring an additional 27 shares in the last quarter. Advance Capital Management Inc. raised its position in Intuitive Surgical by 3.8% during the first quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after acquiring an additional 27 shares in the last quarter. Sheaff Brock Investment Advisors LLC raised its position in Intuitive Surgical by 1.3% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 2,226 shares of the medical equipment provider’s stock valued at $751,000 after acquiring an additional 29 shares in the last quarter. Liberty Capital Management Inc. raised its position in Intuitive Surgical by 3.8% during the fourth quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock valued at $275,000 after acquiring an additional 30 shares in the last quarter. Finally, NBC Securities Inc. raised its position in Intuitive Surgical by 34.4% during the first quarter. NBC Securities Inc. now owns 121 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 31 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.